Analysis Of Clinical Characteristics And Treatment Evaluation Of 87 Patients With Pituitary Growth Hormone Tumors

Objective To analyze the clinical characteristics and outcomes of patients with pituitary growth hormone tumors,to discuss the risk factors associated with unremitting postoperative growth hormone tumor patients,and to propose standardized treatment pathways and effective measures to improve the prognosis of pituitary growth hormone tumors.Methods Collection of patients with pituitary growth hormone adenoma hospitalized in XXX Hospital from 2012-2022,and a retrospective study was conducted to statistically analyze the relationship between clinical characteristics and treatment prognosis of patients with pituitary growth hormone adenoma using general clinical characteristics,biochemical indices,hormone levels,imaging tests,treatment methods,complications,postoperative pathology,and disease regression.Results A total of 87 patients with growth hormone adenoma who underwent endoscopic transsphenoidal-pituitary sinus approach for pituitary lesion resection at the Hospital of XXX were collected,with a mean hospital age of 42.24 ± 1.21 years.Most of the patients presented for the first time with symptoms of tumor compression,while the rest presented with typical signs of acromegaly or endocrine disorders.As the tumor diameter increased,GH levels increased accordingly(P< 0.05).Assessment of preoperative pituitary function revealed that decreased preoperative pituitary function was most common in hypogonadal axis(86.4%),and there were significant differences in gender and tumor diameter between the hypofunctional and non-hypogonadal groups(P< 0.05).Risk factors predicting the development of decreased pituitary function after surgery included tumor diameter and preoperative hypopituitarism,with tumors ≥2.25 cm in diameter most likely to have postoperative hypopituitarism(P < 0.05)In terms of postoperative outcome assessment,26 cases(29.9%)were in remission after surgery,58 cases(66.7%)were not in remission,and 3 cases(3.4%)were recurrent,surgical treatment significantly reduced GH levels in patients with pituitary growth hormone tumors(P <0.05),and the larger the tumor diameter,the greater the risk of postoperative non-remission in patients with pituitary growth hormone tumors,and the optimal tumor diameter cutoff value for predicting non-remission after surgery was 1.65 cm(P < 0.05).Pharmacological treatment of patients not in remission after surgery improved some clinical symptoms while effectively reducing GH levels(P < 0.05).Conclusion For most patients with pituitary growth hormone tumors,surgery is the best option to achieve satisfactory clinical outcomes,and there is a significant positive correlation between tumor size and GH levels and postoperative remission rates.The independent risk factors for preoperative pituitary function decline are mainly male and tumor diameter,and postoperative hypopituitarism in patients with growth hormone tumors is closely related to tumor diameter and preoperative hypopituitarism,and pharmacological treatment can significantly reduce GH levels in patients with unremitting postoperative pituitary growth hormone tumors and improve clinical symptoms in some patients symptoms.